Volume 6 Supplement 3
Beyond insulin: rethinking cellular metabolism
- Craig B Thompson1
© Thompson; licensee BioMed Central Ltd. 2012
Published: 1 June 2012
The latest cancer therapeutics are almost all inhibitors of oncogenes or their downstream mediators. With the exception of imatinib, most such drugs have been disappointing in the clinic. In contrast, existing successful cancer drugs have a therapeutic index because they render the consequences of oncogene activation selectively toxic to the cancer cell. A renewed focus on this type of approach appears warranted and should be considered.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.